

**ADMINISTRATIVE PROCEEDING**  
**File No. 3-17735**

**Wife and Brother-In-Law of Officer of Atlanta Biotech Charged With Insider Trading**

**December 16, 2016** – The Securities and Exchange Commission today announced insider trading charges against the wife of an officer of an Alpharetta, Ga. biopharmaceutical company and her brother arising from their trading in advance of certain announcements made in October and December 2013 concerning the company’s efforts to obtain U.S. Food and Drug Administration (“FDA”) approval for a prescription drug.

A SEC investigation found that Jo Ann Myers and her brother, Hollis W. Pickett, Jr., obtained material non-public information from her husband, an officer of Alimera Sciences, Inc., concerning Alimera’s new drug application for FDA approval of a drug used to treat diabetic macular edema. Myers then tipped her son and stepmother, leading her son and father to trade in Alimera stock in advance of the October and December 2013 announcements. Pickett traded and directed his son to trade in Alimera stock in advance of the December 2013 announcement. As a result of their trading, they illegally avoided losses and generated profits exceeding \$48,000.

The SEC’s order instituting a settled administrative proceeding finds that Myers and Pickett each violated Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. Without admitting or denying the findings in the SEC’s order, Myers and Pickett each agreed entry of a cease-and-desist order and to pay \$43,168.05 and \$9,211.57 in disgorgement and prejudgment interest and civil penalties totaling \$40,405.69 and \$8,656.50, respectively.

The SEC’s continuing investigation is being conducted by Penny J. Morgan and William S. Dixon in the Atlanta Regional Office. The SEC appreciates the assistance of the Financial Industry Regulatory Authority (FINRA).